WHO Says Expert Committee Will Propose Adoption Of Mpox Vaccines Under Emergency Use Listing Around Mid Sept
Portfolio Pulse from Benzinga Newsdesk
The World Health Organization (WHO) announced that an expert committee will propose the adoption of Mpox vaccines under Emergency Use Listing around mid-September.
August 14, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories (ABT) may see a positive impact as the WHO proposes the adoption of Mpox vaccines under Emergency Use Listing.
As a major player in the healthcare and vaccine market, Abbott Laboratories could see increased demand and positive sentiment from the WHO's proposal.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Emergent BioSolutions (EBS) is likely to experience a positive impact due to WHO's proposal to adopt Mpox vaccines under Emergency Use Listing.
Emergent BioSolutions, a significant player in the vaccine market, is expected to benefit from increased demand and positive market sentiment following the WHO's proposal.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 65
POSITIVE IMPACT
Moderna (MRNA) is likely to experience a positive impact due to WHO's proposal to adopt Mpox vaccines under Emergency Use Listing.
Moderna, being a key player in the vaccine industry, is expected to benefit from increased demand and positive market sentiment following the WHO's proposal.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
SIGA Technologies (SIGA) may see a positive impact as the WHO proposes the adoption of Mpox vaccines under Emergency Use Listing.
SIGA Technologies, involved in vaccine development, could see increased demand and positive sentiment from the WHO's proposal.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 60